Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Clinigen Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Clinigen Acquires Imukin from Horizon Pharma 15
Clinigen Acquires Proleukin from Novartis 16
Clinigen Acquires Rights to Totect from Biocodex USA 17
Clinigen Group Acquires Ethyol from AstraZeneca 18
Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 19
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For US$33 Million 20
Partnerships 21
Clinigen Enters into Distribution Agreement with Lukare Medical 21
Clinigen and Bristol-Myers Squibb Enter into Agreement 22
Clinigen Enters into Agreement with Shionogi 23
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 24
Clinigen Enters into Distribution Agreement with Romark Labs 25
Clinigen Group Enters into Distribution Agreement with BioQ Pharma 26
Clinigen Group Partners with Horizon Pharma 27
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 28
Cumberland Pharma Enters into Agreement with Clinigen 29
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 30
Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 31
Licensing Agreements 32
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 32
Quantum Pharma Enters into Licensing Agreement with Moorfields Pharma 33
Quantum Pharma Enters into Licensing Agreement with Futura Medical 34
German Pharma Company Enters into Licensing Agreement with Colonis Pharma 35
Clinigen Extends Licensing Agreement with Hospira for Foscavir 36
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 37
Quantum Pharma Enters into Licensing Agreements 39
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 40
Equity Offering 41
Clinigen Group to Raise USD105.35 Million in Equity Offering of Shares 41
Clinigen Raises USD105.4 Million in Private Placement of Shares 42
Quantum Pharma to Raise USD18.43 Million in Private Placement of shares 44
Quantum Pharma Raises USD167 Million in IPO 45
Clinigen Completes IPO For US$16 Million 46
Acquisition 48
Clinigen Acquires iQone Healthcare for USD8.8 Million 48
NuPharm Acquires Laboratoire Biodim from Pharma Omnium International 50
Clinigen Acquires Quantum Pharma for USD199 Million 51
Clinigen Group Acquires Link Healthcare for USD78.2 Million 53
Quantum Pharma Acquires NuPharm 54
Clinigen Group Acquires Idis Group for USD338 Million 55
Quantum Pharma Acquires Lamda, Lamda Labs and Lamda Pharma for USD10.4 million 56
Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 57
Clinigen Group Plc – Key Competitors 58
Clinigen Group Plc – Key Employees 59
Clinigen Group Plc – Locations And Subsidiaries 60
Head Office 60
Other Locations & Subsidiaries 60
Recent Developments 62
Financial Announcements 62
Sep 27, 2018: Clinigen Group: Diversified portfolio drives strong financial results 62
Feb 27, 2018: Clinigen Group: Good H1 Performance With Adjusted EPS Up 13% 75
Sep 28, 2017: Clinigen Group: Full Year Results for the Year Ended 30 June 2017 76
Mar 15, 2017: Clinigen Group: Strong H1 Performance with Adjusted EPS up 31% 77
Jan 25, 2017: Clinigen Group HY trading update: strong H1 performance with gross profit up 34% 84
Corporate Communications 86
Mar 06, 2018: Clinigen strengthens senior management team in clinical trial services and commercial medicines 86
Dec 06, 2017: Clinigen Group:Directorate Change 87
Nov 01, 2017: Clinigen Group: Board changes 88
Other Significant Developments 90
Jul 18, 2017: Clinigen Group: Year End Trading Update 90
Appendix 92
Methodology 92
About GlobalData 92
Contact Us 92
Disclaimer 92
Clinigen Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Clinigen Group Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Clinigen Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Clinigen Acquires Imukin from Horizon Pharma 15
Clinigen Acquires Proleukin from Novartis 16
Clinigen Acquires Rights to Totect from Biocodex USA 17
Clinigen Group Acquires Ethyol from AstraZeneca 18
Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 19
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For US$33 Million 20
Clinigen Enters into Distribution Agreement with Lukare Medical 21
Clinigen and Bristol-Myers Squibb Enter into Agreement 22
Clinigen Enters into Agreement with Shionogi 23
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 24
Clinigen Enters into Distribution Agreement with Romark Labs 25
Clinigen Group Enters into Distribution Agreement with BioQ Pharma 26
Clinigen Group Partners with Horizon Pharma 27
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 28
Cumberland Pharma Enters into Agreement with Clinigen 29
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 30
Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 31
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 32
Quantum Pharma Enters into Licensing Agreement with Moorfields Pharma 33
Quantum Pharma Enters into Licensing Agreement with Futura Medical 34
German Pharma Company Enters into Licensing Agreement with Colonis Pharma 35
Clinigen Extends Licensing Agreement with Hospira for Foscavir 36
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 37
Quantum Pharma Enters into Licensing Agreements 39
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 40
Clinigen Group to Raise USD105.35 Million in Equity Offering of Shares 41
Clinigen Raises USD105.4 Million in Private Placement of Shares 42
Quantum Pharma to Raise USD18.43 Million in Private Placement of shares 44
Quantum Pharma Raises USD167 Million in IPO 45
Clinigen Completes IPO For US$16 Million 46
Clinigen Acquires iQone Healthcare for USD8.8 Million 48
NuPharm Acquires Laboratoire Biodim from Pharma Omnium International 50
Clinigen Acquires Quantum Pharma for USD199 Million 51
Clinigen Group Acquires Link Healthcare for USD78.2 Million 53
Quantum Pharma Acquires NuPharm 54
Clinigen Group Acquires Idis Group for USD338 Million 55
Quantum Pharma Acquires Lamda, Lamda Labs and Lamda Pharma for USD10.4 million 56
Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 57
Clinigen Group Plc, Key Competitors 58
Clinigen Group Plc, Key Employees 59
Clinigen Group Plc, Subsidiaries 60
List of Figures
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Clinigen Group Plc, Medical Devices Deals, 2012 to YTD 2018 12